Nagpur: After 90-days of hospitalisation, including 70 days on ventilator support, 11-year-old Viraj returned home on January ...

The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain-Barré syndrome (GBS), which ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS ... with the aim of transforming the global treatment ...

(MENAFN- GlobeNewsWire - Nasdaq) First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in ...

The treatment has received Fast Track and Orphan ... about the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ANX1502 in Cold Agglutinin Disease ...

The treatment has received Fast Track and Orphan Drug designations ... The firm is optimistic about the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ...

Imlifidase is currently being studied in the following autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré Syndrome (GBS). HNSA-5487 is moving quickly ...

BENGALURU: The Karnataka High Court appointed the wife of a retired man as his guardian to operate his three savings bank ...

Guillain-Barré syndrome (GBS) is an acute inflammatory ... that patients whose IgG levels increase less after treatment of GBS with IVIg have worse outcomes compared with those who have larger ...